JPRN-UMIN000033993已完成未知
A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancer - A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancer
Kindai university, Faculty of Medicine, Department of Medical Oncology0 个研究点目标入组 80 人开始时间: 2018年9月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Not established
研究者
相似试验
进行中（未招募）
1 期
A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid TumorsEUCTR2019-000999-42-GBCytomX Therapeutics, Inc162
进行中（未招募）
1 期
A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid TumorsEUCTR2019-000999-42-ESCytomX Therapeutics, Inc160
进行中（未招募）
1 期
A study of CX-072 in Combination with other Anticancer Therapy in Adults with Solid TumorsTreatment of solid tumors, including advanced/unresectable or metastatic cancer and neoadjuvant/resectableMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2019-000999-42-NLCytomX Therapeutics, Inc170
已完成
2 期
A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody* Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072-002)tumor10027476cancerNL-OMON49159CytomX Therapeutics, Inc.,15
招募中
不适用
Observational study for PD1 expression status on peripheral CD4 T cells and PDCD1 SNP as markers of Mycobacterium tuberculosis infection susceptibility.Mycobacterium tuberculosis infectionJPRN-UMIN000032967Respiratory Disease Center, Yokohama City University Medical Center50